Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
University of Cape Town Global Fund Medical Research Council, South Africa |
---|---|
Information provided by: | University of Cape Town |
ClinicalTrials.gov Identifier: | NCT00331708 |
The main purpose of this study is to compare the drug levels of artesunate and sulfadoxine-pyrimethamine found in pregnant women with malaria to those drug levels found in non-pregnant women from other studies. In addition the efficacy and safety of the study drugs will be determined for pregnant women and their babies.
Condition | Intervention |
---|---|
Malaria |
Drug: Artesunate plus sulfadoxine-pyrimethamine |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Pharmacokinetics Study |
Official Title: | An Open-Label in Vivo Drug Study to Evaluate Artesunate Plus Sulfadoxine-Pyrimethamine (ASSP) Pharmacokinetics, Therapeutic Efficacy, Gametocyte Carriage and Birth Outcomes in Pregnant Women With Uncomplicated Falciparum Malaria |
Estimated Enrollment: | 30 |
Study Start Date: | April 2006 |
Estimated Study Completion Date: | June 2007 |
The resistance of Plasmodium falciparum to anti-malarial drugs is a serious impediment to the control of malaria, and this poses a particular problem for the treatment of pregnant women, a group especially vulnerable to malaria; pregnancy increases the risk of disease progression and complications with up to a 10-fold increase in the malaria case fatality rate in areas of low transmission. As falciparum parasites can sequester in the placenta, pregnant women have been shown to develop recrudescence up to 85 days after quinine treatment, and are at increased risk of gametocyte carriage. Artemisinin-based combination therapies have been shown to improve cure rates and to delay antimalarial resistance. In humans the efficacy and safety of artesunate in the treatment of malaria in pregnancy has been studied in over 1000 women in which no evidence of foetal harm was demonstrated. Quinine is the only alternative currently available in Mozambique for treating malaria in pregnancy however there is relatively little data available on its efficacy or safety. There is no published information on the pharmacokinetics of SP in pregnancy, however data show a marked reduction in bioavailability of artesunate and its active metabolite, dihydroartemisinin. Thus, we cannot be confident that the standard dosage regimens of SP and of artesunate are optimal for the treatment of acute uncomplicated malaria in pregnancy or whether altered pharmacokinetics is contributing to the SP-treatment failures observed in pregnancy. This study creates the opportunity to study whether the pharmacokinetic properties of SP and artesunate are altered by physiological changes that occur during pregnancy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Mozambique, Maputo | |
Ndlavela Health Centre | |
Ndlavela, Maputo, Mozambique |
Principal Investigator: | Karen I Barnes, MBChB | University of Cape Town |
Study ID Numbers: | SEACAT2.1 |
Study First Received: | May 30, 2006 |
Last Updated: | April 3, 2007 |
ClinicalTrials.gov Identifier: | NCT00331708 |
Health Authority: | Mozambique: Ministry of Health (MISAU) |
Malaria Efficacy Pharmacokinetic Gametocyte |
Molecular markers Sulfadoxine-pyrimethamine Artesunate Artemisinin |
Folic Acid Artesunate Pyrimethamine Protozoan Infections Sulfadoxine-pyrimethamine Artemisinins |
Artemisinine Parasitic Diseases Malaria Sulfadoxine Malaria, Falciparum |
Anti-Infective Agents Antiprotozoal Agents Molecular Mechanisms of Pharmacological Action Coccidiosis Enzyme Inhibitors Anti-Infective Agents, Urinary Folic Acid Antagonists |
Renal Agents Pharmacologic Actions Antimalarials Antiparasitic Agents Therapeutic Uses Amebicides |